What smart money is saying about Bachem Holding AG
1 fund in our archive has pitched Bachem Holding AG — most recently Baron International Growth Fund in September 2026.
Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. It engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). The company also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services. Bachem Holding AG was incorporated in 1971 and is headquartered in Bubendorf, Switzerland. Bachem Holding AG operates as a subsidiary of Ingro Finanz AG.
Get an email when a fund buys, sells or pitches it
Position history
Every position in Bachem Holding AG on record in the archive was reported in Q3 2026, across 1 fund letter, with 1 buy (opened or added).
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q3 2026 | 1 | 1 | 0 | 1 |
Bought and Sold count moves: the same sentence published by several funds of one house in a quarter counts once.
Fund activity · 1 position · 1 move
- New positionBaron International Growth FundSeptember 2026
“we are also encouraged by the company's ongoing capacity expansion to nearly triple its production by 2030, backed by long-term minimum revenue commitment contracts and prepayments, which provide strong visibility into topline growth over the medium term.”
Bachem Holding AG
Also mentioned · 1
These funds discuss Bachem Holding AG — as a competitor, benchmark or comparable — without disclosing a position in it.
- September 2026
“At the beginning of this year, Codexis had signed three partnerships with contract development and manufacturing organizations (CDMOs): Bachem, Nitto Denko Avecia, and Axolabs, ahead of its goal of one.”
Bachem Holding AG
Fund coverage · 1 thesis
- Baron International Growth FundSeptember 2026
Bachem is a peptide CDMO positioned to benefit from structural peptide drug demand growth, with capacity expansion and reshoring tailwinds supporting ~20% revenue growth.
Read the full thesis
Read every full thesis on Bachem Holding AG
Unlock all 1 thesis — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→